Oncornaviruses of type C morphology cause leukemias, lymphomas, or sarcomas in several vertebrates and have been isolated from many different species (1, 2), including nonhuman primates (3--8). Although an etiologic association between oncornaviruses and human cancer has not been proved, high molecular weight RNA (9-14), reverse transcriptase (9-19), and viral structural proteins (20) similar or identical to those of known mammalian oncornaviruses, particularly the SSV-I/SSAV-I complex (12-14, 16, 18-24), have been demonstrated in human malignant tissue. Isolation of type C virus from cultures of human tumor cells (21-23, 25, 26) and normal embryonic cells (24) has been described. A type C virus (HL-23V) was isolated from cultured peripheral leukocytes and bone marrow cells of an AML patient by Gallagher et al. (21). Previous studies showed that the reverse transcriptase (21) and the p30 (20) , pI2, and gp 71 (27) structural proteins of HL-23V were closely related or identical to those of SSV-I and SSA V-I, both isolated from a naturally occurring fibrosarcoma ofa woolly monkey (4). In addition, it was found that HL-23V-infected cell lines contained a second type C virus, indistinguishable from BaEV (28, 29). Examination of uncultured leukemic blood cells and postmortem tissue from patient HL-23 revealed RNA sequences in cytoplasmic virus-like particles homologous to SSV-l/SSAV-I and BaEV (30) . Identification of BaEV-related DNA proviral sequences in HL-23 spleen (30), as well as peripheral blood cells of 7 other leukemia patients (31), was also reported, but attempts to demonstrate SSV-l/SSAV-I proviral DNA in HL-23 tissues have been unsuccessful. The studies reported here demonstrate that HL-23V-infected cell lines, like SSV-I/ SSA V-I-infected cell lines, produce both transforming and nontransforming virus antigenically indistinguishable from SSV-I/SSAV-I and induce tumors in marmoset monkeys.
Oncornaviruses of type C morphology cause leukemias, lymphomas, or sarcomas in several vertebrates and have been isolated from many different species (1, 2) , including nonhuman primates (3--8) . Although an etiologic association between oncornaviruses and human cancer has not been proved, high molecular weight RNA (9) (10) (11) (12) (13) (14) , reverse transcriptase (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) , and viral structural proteins (20) similar or identical to those of known mammalian oncornaviruses, particularly the SSV-I/SSAV-I complex (12-14, 16, 18-24) , have been demonstrated in human malignant tissue. Isolation of type C virus from cultures of human tumor cells (21-23, 25, 26) and normal embryonic cells (24) has been described. A type C virus (HL-23V) was isolated from cultured peripheral leukocytes and bone marrow cells of an AML patient by Gallagher et al. (21) . Previous studies showed that the reverse transcriptase (21) and the p30 (20) , pI2, and gp 71 (27) structural proteins of HL-23V were closely related or identical to those of SSV-I and SSA V-I, both isolated from a naturally occurring fibrosarcoma ofa woolly monkey (4) . In addition, it was found that HL-23V-infected cell lines contained a second type C virus, indistinguishable from BaEV (28, 29) . Examination of uncultured leukemic blood cells and postmortem tissue from patient HL-23 revealed RNA sequences in cytoplasmic virus-like particles homologous to SSV-l/SSAV-I and BaEV (30) . Identification of BaEV-related DNA proviral sequences in HL-23 spleen (30) , as well as peripheral blood cells of 7 other leukemia patients (31) , was also reported, but attempts to demonstrate SSV-l/SSAV-I proviral DNA in HL-23 tissues have been unsuccessful. The studies reported here demonstrate that HL-23V-infected cell lines, like SSV-I/ SSA V-I-infected cell lines, produce both transforming and nontransforming virus antigenically indistinguishable from SSV-I/SSAV-I and induce tumors in marmoset monkeys.
MATERIALS AND METHODS
Cells.-Dog thymus cells (FCf2th-A7573; Naval Biomedical Research Laboratory, Oakland, Calif.) and horse skin cells (R-1042; supplied by Dr. J. Rhim, Microbiological Associates, Bethesda, Md.) were maintained in Eagle's basal medium (Gibco, Grand Island, N.Y.) improved with nonessential amino acids and supplemented with 10% (heat-inactivated) FCS (Reheis Chemical Co., Phoenix, Ariz.). Marmoset skin (HF) and lung (1283) cell lines were maintained in RPMI-I640 (Gibco) with 10% FCS. We established the marmoset tumor cell culture by mincing excised tissue and explanting 1 mrn" pieces in 25-cm 2 flasks with 2 ml of RPMI-I640 supplemented with 20% FCS. When sufficient outgrowth occurred, explant cultures were treated with 0.25% trypsin-EDTA and plated in new flasks.
Virus.-A dog thymus cell line infected with virus produced by HL-23 AML cells in culture (28) was supplied by Dr. R. Gallo (National Cancer Institute, Bethesda, Md.) and was the source of HL-23V. This cell line, designated A7573(HL-23V), and other HL-23V-infected cultures were handled and incubated in a laboratory remote from other oncornavirus work, and all possible precautions were taken in use of media and materials to avoid contamination. An SSV-I-transformed marmoset fibroblastic cell line, HF(SSV-I/ SSA V-I), was the source of SSV-I/SSAV-I. Virus-producing cells were plated at 1-2 X 10 6 cells/flask (75 em") on day 1. Supernatants were collected on day 4, passed through a 0.45 J,L Millipore filter (Millipore Corp., Bedford, Mass.), and stored at -70 0 C. Anima/s.-Four white-lipped marmosets (Saguinusfuscicollis nigrifrons, S. j. illigeri), born in our breeding colony and hand-reared by established procedures, were inoculated when 3-5 days old im or ip with 3-7x 10 virus as described above. Cultures infected beyond the end point of focus induction were subcultured twice. A mixed culture cytopathogenicity test with XC cells was performed as described by Rangan et al. (32) . The titer is expressed as the reciprocal of the highest dilution that induced syncytia (~8 nuclei/syncytium).
Indirect immunojluorescence.-Acetone-fixed cell monolayers were treated with marmoset plasma diluted with 2.5% bovine serum albumin in PBS for 30 minutes at 37°C. After two washes with PBS, monolayers were reacted with fluorescein-conjugated goat antihuman IgG (Hyland Laboratories, Los Angeles, Calif.) for 30 minutes at 37°C, washed two times, and mounted.
Neutralization tests.-Twofold dilutions of serum or plasma in a final volume of 0.6 ml were incubated at 4°C for 4 hours with 0.6 ml virus at a dilution calculated to produce 50 foci/f1ask. Dilutions were made with HBSS containing 2% agamma FCS. Neutralization of focusforming virus was determined by focus assay.
Chromosome preparations.-Chromosomes were prepared according to the method of Moorhead and Nowell (33) . Slides were stained with Giemsa diluted in Sorensen's buffer at pH 6.8-7.4 at a concentration of one Pasteur pipette drop of dye to 1 ml of buffer. Mitoses arrested in metaphase were photographed with a Zeiss photomicroscope on Kodak high-contrast copy film. Prints were made on 8x lO-inch paper. Prints of chromosomes from the best mitoses were cut out, paired, and analyzed. Interference between HL-23V and SSV-I was tested by infection of normal marmoset cells with tenfold dilutions of HL-23V, subculture of focus-free cultures, and then challenge of the subcultures with SSV-I or HL-23V. SSV-I and HL-23V focus formation was inhibited in cultures infected with HL-23V at 10-and 100-fold dilutions beyond the focus end point (table 2) . Parallel cultures infected with HL-23V and not challenged were positive for syncytial formation in the MC test and for type C virus by electron microscopy through dilutions 100-fold beyond the focus end point, corresponding to the interference end point. Cultures infected with virus at greater than 100-fold dilutions beyond the focus end point were negative by all three tests. and HL-23V plasma gave the same end points whether titered on SSV-ISSAV-l-or HL-23V-infected marmoset skin or dog thymus cells. The antigenic properties of HL-23V produced by dog thymus cells (A7573) or the marmoset tumor cell culture (75-BF-l) were compared with those of SSV-l by neutralization tests (table 5) . Marmoset SSV-l/SSAV-l and GALV antisera neutralized SSV-I and HL-23V equally well, whereas a marmoset antiserum to FeSV (SnyderTheilen strain) failed to neutralize either virus. HL-23V produced by 75-BF-l cells at passage 4 was neutralized by the goat anti-SSV-I/SSAV-I serum as effectively as SSV-I, and the neutralizing titer of the marmoset Oncogenicity of HL-23V was investigated by inoculation of 4 newborn marmosets with 3-7x 10 7 A7573(HL-23V) cells (table 3) . Of 3 marmosets inoculated im, 2 developed palpable tumors by 4 weeks PI; the tumor in I animal had regressed completely by 6 weeks, and the tumor in the other animal, 75-BF-l, was partially excised 6 weeks PI when undergoing regression. After surgery, the residual mass slowly enlarged for 12 weeks and then regressed; a small mass was still present 28 weeks PI when the animal died of acute pneumonia. Both tumor specimens from 75-BF-l were fibromas composed of fibroblasts, abundant collagen, and some lymphoid cells; virus particles budding from fibroblasts and extracellular type C virus were observed by electron microscopy. Total and differential leukocyte counts, monitored monthly in all 4 animals, remained normal throughout the observation period. Two animals that never developed detectable tumors and the 1 animal that developed a regressor tumor were clinically normal 10 months PI. The behavior and morphology of HL-23V-induced marmoset tumors were similar or identical to those of SSV-I-induced tumors (4-6). All 4 marmosets developed antibodies that reacted with HL-23V antigens in indirect immunofluorescence tests (table 2) . Peak antibody titers were highest, I :4,096, in the animal with the prolonged clinical course (75-BF-I).
RESULTS

Filtered
Cell cultures were established from 75-BF-l tumor tissue obtained at biopsy and autopsy; they were identified as marmoset cells by karyotype analysis. The morphology and growth pattern of the cultures closely resembled those of the cells transformed in vitro by HL-23V or SSV-I (34); budding particles and extracellular type C virus were readily apparent by electron microscopy. Filtered supernatant, collected from passage 7 of the biopsy culture and from passage 2 of the autopsy culture, contained 1X 10 4 and I X 10 5 FFU/ml respectively, of a transforming virus and a tenfold excess of nontransforming virus. Nonidet P-40 disrupted virus from cultured tumor cells reacted with goat anti-SSV-I/ SSA V-I p30 in an immunodiffusion test with a line of complete identity; p30 antigen indistinguishable from SSV-l/SSAV-l p30 was identified in 75-BF-I(HL-23V) cultured cells by competition radioimmunoassay, but no BaEV p30 was detected by this technique (Parks W; Personal communication).
HL-23V and SSV-l/SSAV-I were compared by titration of marmoset anti-SSV-l/SSAV-l serum and anti-HL-23V plasma by the indirect immunofluorescence technique, with the use of SSV-I/SSAV-l-and HL-23V-infected cell monolayers (table 4) . The anti-SSV-l serum plasma (75-BF-l) was the same against SSV-l or HL-23V produced by 75-BF-l tumor cells and was only twofold lower against HL-23V produced by dog thymus cells. In addition, we observed the appearance of 2-8 foci when HL-23V produced by dog thymus or marmoset cells was reacted with SSV-l/SSAV-I antiserum or anti-HL-23V marmoset plasma at low dilutions. The breakthrough of focus-forming virus at low serum dilutions was never observed in neutralization tests with SSV-l/SSAV-l.
DISCUSSION
Studies reported here demonstrated that HL-23V-infected cells produced not only SSAV-l, as reported previously (28, 29) , but also the sarcomagenic component of the simian sarcoma virus complex. HL-23V readily transformed marmoset cells in vitro and the transformed cell lines produced levels of transforming and nontransforming virus comparable to those pro-. duced by the SSV-l-transformed marmoset cell lines. The HL-23V-transforming activity, independently confirmed in another laboratory (Ting RC: Personal communication), was detected when first tested in our laboratory 1 week after receipt of the A7573(HL-23V) cell line and was reproducible with A7573(HL-23V) frozen culture fluids stored at that time, as well as with fresh culture fluids. In contrast to our findings, Teich et al. (28) did not report transformation of marmoset cells by HL-23V and, furthermore, cited the poor growth of HL-23V in marmoset cells, as measured by XC plaque assay, as evidence for the nonidentity of HL-23V and SSA V-I. To the best of our knowledge, the protocol for assay of focus-forming virus, as first described by this laboratory (34) , was not performed in that study.
HL-23V-infected dog thymus cells, like SSV-l-transformed marmoset cells, induced fibromas when inoculated into marmosets, and the tumor cells established in culture produced virus indistinguishable from SSV-l/ SSAV-I and HL-23V grown in dog thymus cells. Tumor induction in marmosets by inoculation of cellfree preparations of HL-23V was not attempted due to the low levels of transforming virus produced by HL-23V-infected cells and to the difficulty experienced in the demonstration of oncogenicity in marmosets with cellfree SSV-l previously, where only 1 of 6 inoculated monkeys developed tumors (5). Because HL-23V produced directly by the human myeloblasts was not available, it was impossible to test the oncogenicity of such preparations. Induction of leukemia in marmosets by SSAV-1 has not been tested directly; however, leukemia has never been observed in monkeys inoculated with cellfree SSV-l/SSAV-l or cells infected with SSV-l/ SSA V-lor HL-23V, both of which produce excess nontransforming associated virus.
Though studies reported previously demonstrated the presence of a BaEV component in A7573 cells infected with HL-23V (28, 29) , no BaEV p30 was detected in the cultured marmoset tumor cells, and the tumor cells did not induce syncytial formation in MC tests with KB cells. This finding does not eliminate the possibility of BaEV information in HL-23V-infected marmoset J NATL CANCER INST cells; however, attempts to infect marmoset cells in vivo and in vitro with BaEV were unsuccessful in previous studies performed in our laboratory (unpublished data).
Neutralization and interference tests, in which inhibition of HL-23V focus induction was measured, failed to distinguish between HL-23V and SSV-l, in agreement with results reported by Teich et al. (28) who used an HL-23V pseudotype of murine sarcoma virus. The twofold differences of serum antibody titers observed in some neutralization tests are generally not considered significant, and though these tests were repeated several times with similar results, it is doubtful that they indicate true antigenic differences between SSV-l/SSAV-I and HL-23 V. We are, however, investigating the possibility that the few transforming virus particles not neutralized by low dilutions of high-titered anti-HL-23V plasma or anti-SSV-l serum may represent hybrid viruses, i.e., a phenotypic mix, heterozygotes, or recombinants, resulting from interaction of HL-23V and another virus, possibly the BaEV component detected previously in HL-23V preparations.
Inasmuch as our results agreed with earlier reports of the genetic and antigenic identity of HL-23V and SSV-l/ SSA V-I (27, 29) and, in addition, demonstrated that the biologic and oncogenic properties of HL-23V and SSVl/SSAV-I were indistinguishable, the question of the true origin of these viruses remains open to further experimental analysis and speculation. Viral contarninati~m of the AML cells in culture is a possibility, and a difficult one to disprove. The association of both sarcomagenic (SSV-l/SSAV-I) and endogenous (BaEV) viruses with a human leukemia is surprising, however, because neither of these viruses has been associated with leukemias in their natural or experimental hosts. Nevertheless, it is of interest that the isolation of both BaEVand SSV-l-related viruses from human embryonic tissues was reported recently by Panem et al. (26, 35) , and nucleic acid sequences related to these viruses have been demonstrated in uncultured leukocytes and postmortem spleen tissues of patient HL-23V (30) . But even if it can be confirmed that these viruses are really present in the human population, the role of SSV-l, SSAV-l, or BaEV-related viruses in human neoplasia has yet to be proved.
